{"denoms":[{"counts":[{"groupId":"BG000","value":"277"},{"groupId":"BG001","value":"140"},{"groupId":"BG002","value":"417"}],"units":"Participants"}],"groups":[{"description":"Participants received Guadecitabine 60 mg/m\\^2, SC, on Days 1-5 of each 28-day cycle for at least 6 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy. Participants received Guadecitabine treatment beyond 6 cycles as long as the participant continued to benefit based on investigator judgment and participant response and tolerability (or up to a maximum of 36 cycles).","id":"BG000","title":"Guadecitabine"},{"description":"Participants received one of the three treatment choice options:\n\n1. LDAC 20 mg/m\\^2 SC/IV once daily for 14 days of each 28-day cycles for at least 4 cycles in absence of disease progression or unacceptable toxicity.Participants who were responding or had stable disease were to continue treatment as per standard institutional practice.\n2. Standard IC of a 7+3 regimen:Cytarabine 100-200 mg/m\\^2/day given as continuous infusion for 7 days and anthracycline(daunorubicin(45-60 mg)/idarubicin(9-12 mg)/mitoxantrone(8-12 mg)/m\\^2) by IV infusion for 3 days of each 28-day cycles.\n3. BSC as needed during the treatment included,but was not limited to,blood transfusions(RBCs or platelets),growth factors including erythropoiesis stimulating agents,granulocyte stimulating factors,iron chelating therapy,and broad-spectrum antibiotics and/or antifungals.\n\nDuration for treatment choice was as per locally approved prescribing information and institutional standard practice or up to a maximum 30 cycles.","id":"BG001","title":"Treatment Choice"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7","value":"73.5"},{"groupId":"BG001","spread":"6.1","value":"73.7"},{"groupId":"BG002","spread":"6.7","value":"73.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"127"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"194"},{"groupId":"BG001","value":"96"},{"groupId":"BG002","value":"290"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"31"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"225"},{"groupId":"BG001","value":"117"},{"groupId":"BG002","value":"342"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"44"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"97"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"179"},{"groupId":"BG001","value":"86"},{"groupId":"BG002","value":"265"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"45"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"The Efficacy Analysis Set included all participants randomly assigned to the study treatment."}